ImmunoMet Therapeutics to Present at the 9th Annual BioShowcase Conference in San Francisco > Announcements

본문 바로가기


Announcements

ImmunoMet Therapeutics to Present at the 9th Annual BioShowcase Conference in San Francisco

페이지 정보

Writer Immunomet Data17-01-06 09:24

Contents

news_logo.png

 

ImmunoMet Therapeutics to Present at the 9th Annual

BioShowcase Conference in San Francisco

 

Houston, TX, January 5, 2017 -- ImmunoMet Therapeutics, a development stage

biotechnology company focused on immuno-oncology and immune cell metabolism,

today announced that Benjamin R. Cowen, PhD, MBA, Chief Operating Officer, will

present at the 9th annual BioShowcase on Tuesday, January 10 at 8:45am at the

Hilton San Francisco Union Square, room 9, ballroom level.

 

Dr. Cowen will provide an overview of the ImmunoMet’s development pipeline. The

Company’s lead molecule, IM156, an OXPHOS inhibitor, has demonstrated positive

in vivo results in resistant brain and lung tumors in preclinical studies. ImmunoMet

expects IM156 to enter a Phase 1 clinical trial in the first half of 2017. Additionally,

the Company’s immuno-oncology program is being developed in combination with

immunotherapies, including an anti-PD1; it is in late stage lead-optimization and

has demonstrated tumor regression in a renal cancer model.

 

About ImmunoMet Therapeutics

ImmunoMet Therapeutics, a private, early stage biotechnology company, is

dedicated to developing innovative oncology products to improve the quality of

life and make a meaningful difference in the lives of cancer patients. The

Company, a spinoff of HanAll, a Korean biopharma company, is headquartered at

JLABS in Houston. ImmunoMet’s R&D program is focused on utilizing cellular

metabolism to develop novel cancer and immuno-oncology therapies, which

include cancer metabolism designed to disrupt a tumor’s energy source using

OXPHOS inhibitors to treat drug resistant and relapse cancers and immuno-

oncology targeting immune suppressor cells to enhance the response of current

immunotherapies. For more information about the Company, please visit

www.immunomet.com.

 

Contact

Joseph T. Schepers:  919-616-1923, joeschepers@immunomet.com

 


Copyright © ImmunoMet. All rights reserved.